Lidocaïne Hcl B. Braun

Lidocaine, the active ingredient in Lidocaïne Hcl B. Braun, is a local anesthetic presented as a sterile solution for epidural, intradermal and intramuscular use. It provides reversible loss of sensation for minor surgical, diagnostic and analgesic procedures in adult patients. GNH USA supplies Lidocaïne Hcl B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lidocaine is a local anesthetic used in procedures that require temporary nerve blockade. - Minor surgical or diagnostic procedures: provides reversible loss of sensation at the injection site. - Epidural analgesia: enables pain relief during labor or postoperative periods. - Intradermal testing for allergic reactions: used to assess hypersensitivity responses.

Lidocaine may cause a range of adverse reactions, most of which are related to the site of administration or systemic absorption.

Common Side Effects: - Transient burning or stinging at the injection site - Tingling or numbness in the treated area - Mild hypotension or dizziness - Nausea or mild headache - Local swelling or erythema

Serious or Rare Side Effects: - Systemic toxicity (CNS symptoms such as seizures, cardiac arrhythmias) - Allergic reaction including anaphylaxis - Methemoglobinemia - Severe hypotension or cardiovascular collapse - Persistent paresthesia or nerve injury

Before using Lidocaïne Hcl B. Braun, consider the following safety measures. - Assess patient allergy: verify no known lidocaine hypersensitivity. - Monitor cardiovascular status: observe blood pressure and heart rate during administration. - Use appropriate dose: calculate based on patient weight and procedural requirements. - Avoid concurrent use with other local anesthetics: reduces cumulative toxicity risk. - Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocaine can interact with several drug classes, influencing its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase cardiotoxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive effects. - General anesthetics (e.g., propofol, sevoflurane): additive central nervous system depression. - Other local anesthetics: cumulative toxicity risk when combined.